Avantor (AVTR) Lifts Guidance As Growth Returns But Is The Rally Fully Valued
Why Avantor Raised Full Year Guidance After Q2 Results
Avantor (AVTR) raised its full year guidance after returning to organic growth in its distribution business, with the VWR segment showing earlier than expected improvement and the Revival program delivering measurable operational progress.
The updated outlook follows second quarter 2026 earnings, where Avantor reported sales of US$1,692.3 million and net income of US$38.1 million, alongside modestly higher first half sales and lower net income versus the prior year period.
See our latest analysis for Avantor.
Avantor's raised guidance and return to organic growth have come alongside a sharp shift in sentiment, with a 30 day share price return of 39.24% and a 90 day share price return of 63.54% contrasting with a five year total shareholder return that declined 64.81%. This suggests recent momentum is building off a much weaker long term base.
If you are looking beyond Avantor to see what else is gaining attention in the market right now, it could be a good moment to broaden your search and check out 20 top founder-led companies
After a 63.54% move in 90 days but a five-year return that declined 64.81%, Avantor now sits at an interesting crossroads. Does the current valuation still leave enough upside for new buyers?
Most Popular Narrative: 31.8% Overvalued
Avantor's most followed narrative pegs fair value at $10.31, which sits below the recent $13.59 close and frames the current rally as stretched against those assumptions.
The global growth in demand for biopharmaceuticals and healthcare solutions is being reinforced by Avantor's major contract wins and extensions with large pharma and biotech consortia. These positions Avantor to capture greater market share as end-market funding and patient procedures return to normalized or higher levels, creating sustained potential for above-market revenue growth.
Curious how that growth story translates into a specific fair value? The narrative leans on gradual revenue expansion, a profit margin rebuild, and a future earnings multiple that assumes real execution progress. The discount rate is set, the time frame is defined, and the gap to today’s price is clear. The missing piece is seeing exactly how those moving parts fit together.
Result: Fair Value of $10.31 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Avantor still faces pressure from competitive pricing that could weigh on margins, and elevated leverage of around US$8.9b in market value, which can limit flexibility.
Find out about the key risks to this Avantor narrative.
Another View on Avantor's Valuation
The analyst narrative tags Avantor as 31.8% overvalued at $13.59 versus a $10.31 fair value, based on earnings assumptions. Yet the current P/S ratio of 1.4x is far below the US Life Sciences industry at 4.1x and peers at 3.3x, and also below a 3x fair ratio. That gap implies the market is treating Avantor cautiously. Is that a warning sign or a potential opportunity if the earnings story improves?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With sentiment on Avantor now split between caution and optimism, it makes sense to review the data yourself and decide where you stand. To see a concise view of both the concerns being raised and the potential rewards investors are focused on, start with 3 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Avantor?
If Avantor has your attention, do not stop here. Fresh ideas from different corners of the market can help you build a stronger and more resilient portfolio.
- Target higher yield potential by reviewing companies in the 8 dividend fortresses that may help support a steady income stream.
- Spot potential value opportunities early by scanning the screener containing 19 high quality undiscovered gems before other investors catch on.
- Keep risk in check by focusing on the 79 resilient stocks with low risk scores that aim to balance return potential with greater resilience.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com